OK
The material selection platform
Adhesives Ingredients
The material selection platform
Adhesives Ingredients
Product News

Master Bond Launches Non-cytotoxic Epoxy Adhesive for Medical Devices

Published on 2021-10-12. Edited By : SpecialChem

TAGS:  Epoxy Adhesives    

Master-bond-nontoxic-epoxy-adhesive Master Bond EP62-1HTMed is a two-part epoxy that meets the requirements of ISO 10993-5 for non-cytotoxicity and therefore can be utilized in many medical device applications. It features high temperature resistance, good flow properties and is suitable for bonding, sealing and coating.

Long-working Life and Optimal Performance


EP62-1HTMed has an advantageously long working life of 12-24 hours for a 100-gram mass and requires moderate heat for curing. Cure schedule options are 60-70 minutes at 176-212°F [80-100°C] or 20-30 minutes at 257°F [125°C].

Post curing at 212-302°F [100-150°C] for 3-5 hours is recommended to achieve optimal performance properties. The epoxy contains no solvents or diluents and has low shrinkage upon cure with a hardness of 80-90 Shore D. This system has a mix ratio by weight of 100 to 5 and can be supplied in standard sized units: ½ pint, pint, quart, and gallon kits. It can also be packaged in premixed and frozen syringes, which ensures that there is no mixing involved and makes it compatible for automated dispensing systems to streamline production.

This product resists repeated sterilization cycles, including STERRAD® and autoclaving. It is also capable of withstanding exposure to gamma radiation, ethylene oxide, bleach as well as other aggressive sterilant and chemicals. EP62-1HTMed offers a tensile strength of 10,000-11,000 psi and adheres well to a variety of similar and dissimilar substrates, including metals, plastics, rubbers, ceramics and composites. This electrically insulative compound has a volume resistivity of more than 1014 ohm-cm, a glass transition temperature of 150-155°C and is serviceable from -60°F to +450°F [-51°C to +232°C].

Source: Master Bond

epo


Channel Alerts

Receive weekly digests on hot topics

Back to Top